Dr John Kruse
@drjohnkruse·16.8K subscribers·484 videos
Centanafadine for ADHD? - Maybe a Triple Reuptake Inhibitor for ADHD
Posted
June 12, 2025
Views
1,808
Likes
58
Comments
7
Engagement
3.60%
June 12, 2025
1,808
58
7
3.60%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
14:41Now PlayingMain Chapters:
Otsuka Pharmaceuticals has released Phase III study results showing that the serotonin-norepinephrine-dopamine reuptake inhibitor centanafidine is effective in treating ADHD ins adults. Further studies and FDA approval could come as soon as this year (2024). This would make it the first drug with this mechanism of action profile to be approved for treating ADHD.
Although there are no head to head trials comparing centanafadine to other medications for ADHD, a research group recently published a matching-adjusted indirect comparison study, looking at how centanafadine appears to contrasts with Vyvanse (lysdexamfetamine), Strattera (atomoxetine), and Qelbree (viloxazine). Centanafadine appears as effective as the non-stimulants, but not quite as powerful as Vyvanse in addressing ADHD symptoms. However, it appeared to have a lower risk for multiple side effects compared to any of these three alternatives.
We should learn in the months head whether these preliminary results hold up - early studies on other triple reuptake inhibitors were encouraging but not robust enough for pharmaceutical companies to continue pursuing approval. Some have cautioned that dopamine reuptake inhibitors may possess greater risks of addiction than do other non-stimulants, but this too, remains to be verified.
-----
Follow on Medium for hundreds of full length articles on this subject and more!
Access to full Medium articles requires paid membership.
-----
References:
Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder (2022)
Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release (2024)
Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies (2020)
Neurotransmitter transmitter occupancy following administration of centanafadine sustained released tablets: A phase 1 study in healthy male adults (2022)
The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium (2024)
Full Chapter list:
Streamed live June 26, 2024
-------------------------
Psychiatrist, neuroscientist, and author John Kruse, MD, PhD presents practical, actionable, well-researched information about treatment options that scientists and clinicians recommend for adult ADHD and other mental health conditions.
Subscribe if you're curious about how neuroatypical brains can optimize their functioning in our shared, and somewhat strange, world.
ADHD topics have a pink background, and those on more general mental health topics have a purple background. A small collection of Politics related videos have an orange background.
Dr. Kruse has posted videos in the "Videos", "Live", and "Shorts", sections of this channel.
You're welcome to email him with topics you want discussed or people you think he should interview.
drjohnkruse@gmail.com
#health #mentalhealth #adhd #centanafadine
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
